clinical trial · NCT05939947
A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis
Advanced Liver FibrosisLiver CirrhosisALE.F02Placebo
brief summary
The purpose of this study is to evaluate how a human body processes ALE.F02 (pharmacokinetics profile) in patients with impaired liver function.
started
Apr 1, 2023
primary completion
Oct 30, 2024
completion
Oct 30, 2024
last updated
Dec 3, 2024
official title
A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol